ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition
On January26, 2018, AbbVie Inc. issued a press release announcing financial results for the fourth quarter ended December31, 2017. A copy of the press release is furnished as Exhibit99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
AbbVie Inc. ExhibitEX-99.1 2 abbv-20171231xexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results •Reports Full-Year Diluted EPS of $3.30 on a GAAP Basis; Adjusted Diluted EPS of $5.60 Reflects Growth of 16.2 Percent•Delivers Full-Year Net Revenues of $28.216 Billion; Adjusted Net Revenues Increased 10.1 Percent on an Operational Basis•Full-Year Global HUMIRA Sales of $18.427 Billion Increased 14.6 Percent on a Reported Basis,…To view the full exhibit click here
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
